KGX 103
Alternative Names: KGX-103Latest Information Update: 06 Oct 2022
At a glance
- Originator KangaBio
- Class Antineoplastics; Cytokines; Immunotherapies
- Mechanism of Action Cytokine replacements; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Sep 2022 Preclinical trials in Solid tumours in China (Parenteral) prior to September 2022 (KangaBio website, September 2022)